Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Liu, Z.
Right arrow Articles by Finelli, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, Z.
Right arrow Articles by Finelli, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1998 Oxford University Press

research-article

Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995

Zhiyuan Liu, Kenneth L Shilkret and Lyn Finelli

New Jersey Department of Health and Senior Services, Division of, Communicable Diseases Po Box 369. 3635 Quakerbrldge Road, Trenton, NJ 08625-0369, USA

BACKGROUND: In a nationwide survey in 1991, the proportion of Mycobacteriurn tuberculosis isolates resistant to both isoniazid and rifampin (MDR-TB) in New Jersey (6.6%) was ranked second highest in the United States. The objectives of this study were to describe drug-resistant TB trend and to investigate risk factors for TB patients with isolates resistant to isoniazid or rifampin or both.

METHODS: TB surveillance data in New Jersey from 1991–1995 were analysed. Data on Mycobacterium tuberculosis culture and drug susceptibility testmg of all TB isolates were obtained from public health and clinical laboratories. Logistic regression was performed to calculate odds ratios (OR) and 95% confidence intervals (CI) and to adjust for potential confounders.

RESULTS: From 1991 to 1995, the proportion of MDR-TB was 5.7%, 4.1%, 2.7%, 3.3% and 2.6%, respectively. There was 10.6% isoniazid resistance and 4.3% nfampin resistance among TB patients in 1993–1995. As expected, recurrent TB was the most important risk factor for resistance to isoniazid (OR = 4.5, 95% CI: 2.6–7.6), rifampin (OR = 5.5, 95% CI: 2.8–11) or both (OR 6.1, 95% CI: 2.9–13). HIV infection was significantly associated with MDR-TB (OR = 3.6, 95% CI: 1.5–8.8). Drug resistance was not found to be significantly associated with homelessness, injecting drug use and excess alcohol use.

CONCLUSION: The proportion of MDR-TB in New Jersey declined significantly from 1991 to 1993. but remained at a plateau from 1993–1995. The results suggest that continuous efforts should be directed at the prevention of MDR-TB among people infected with liv and at improving the proportion who complete chemotherapy among those with TB.

Keywords Tuberculosis, drug resistance, trend, risk factors

Accepted 23 April 1997


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Clin. Microbiol.Home page
W. C. Yam, C. M. Tam, C. C. Leung, H. L. Tong, K. H. Chan, E. T. Y. Leung, K. C. Wong, W. W. Yew, W. H. Seto, K. Y. Yuen, et al.
Direct Detection of Rifampin-Resistant Mycobacterium tuberculosis in Respiratory Specimens by PCR-DNA Sequencing
J. Clin. Microbiol., October 1, 2004; 42(10): 4438 - 4443.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
Z. Liu, K. L. Shilkret, and H. M. Ellis
Predictors of Sputum Culture Conversion Among Patients With Tuberculosis in the Era of Tuberculosis Resurgence
Arch Intern Med, May 24, 1999; 159(10): 1110 - 1116.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.